Intellipharmaceutics International Inc. (IPCI) Receives New Coverage from Analysts at Brean Capital
Brean Capital started coverage on shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) in a research report sent to investors on Monday morning. The brokerage issued a buy rating and a $8.00 price objective on the stock.
Other analysts also recently issued research reports about the company. Zacks Investment Research upgraded Intellipharmaceutics International from a hold rating to a buy rating and set a $2.00 price target for the company in a research report on Tuesday, September 13th. Maxim Group reiterated a buy rating on shares of Intellipharmaceutics International in a research report on Friday, July 22nd.
Intellipharmaceutics International (NASDAQ:IPCI) traded up 2.400% during mid-day trading on Monday, reaching $2.304. 142,168 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $1.90 and a 200-day moving average of $1.83. Intellipharmaceutics International has a one year low of $1.41 and a one year high of $3.19. The stock’s market cap is $66.23 million.
Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings results on Wednesday, July 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01. Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 325.20%. On average, equities research analysts anticipate that Intellipharmaceutics International will post ($0.28) earnings per share for the current year.
A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC bought a new position in Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned 0.27% of Intellipharmaceutics International as of its most recent filing with the SEC. 1.30% of the stock is owned by institutional investors.
About Intellipharmaceutics International
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Stock Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related stocks with our FREE daily email newsletter.